Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

RATINGS CHANGES

Akorn (AKRX) was downgraded to underperform from buy at Bank of America/Merrill Lynch. $22 price target. The company is facing potential risks on several fronts, analysts said. 

Biogen (BIIB) was upgraded to overweight from neutral at Piper Jaffray. $335 price target. The valuation is reasonable, given opportunities in Alzheimer's and SMA, Piper said. 

BioMarin (BMRN) was downgraded to neutral from overweight at Piper Jaffray. $84 price target. The valuation is less attractive, given limited visibility, Piper said. 

Ford (F) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: F.

GoPro (GPRO) was downgraded to underperform from buy at Bank of America/Merrill Lynch. $10 price target. Earnings estimates were also cut, given the company's new guidance, analysts said. 

Impax (IPXL) was downgraded to underperform from neutral at Bank of America/Merrill Lynch. $19 price target. The company may miss 2016 targets, analysts said. 

ITT (ITT) was upgraded to overweight from sector weight at Keybanc. The valuation is more attractive, based on a $40 price target, Keybanc said. 

L Brands (LB) was downgraded to underperform at Jefferies. $50 price target. The company is facing increased competition and earnings are now expected to decline in 2018, Jefferies said. 

Parker Hannifin (PH) was upgraded to overweight at Morgan Stanley. $139 price target. The company is reasonably valued and can delivery above-average earnings growth in the coming quarters, Morgan Stanley said. 

Premier (PINC) was downgraded underperform from buy at Bank of America/Merrill Lynch. $30 price target. The specialty pharma business is posing greater risk, analysts said. 

Take-Two Interactive Software (TTWO) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: TTWO.

Time Warner (TWX) was upgraded to outperform from neutral at Credit Suisse. $107.50 price target. Regulatory pessimism appears overdone, Credit Suisse said. 

Xerox (XRX) was downgraded to underweight at Morgan Stanley. $9.50 price target. BPO and document technology performance remains weak, Morgan Stanley said. 

This article was written by a staff member of TheStreet.

More from Stocks

Dow Trades Above 25,000 as U.S.-China Trade Tensions Thaw

Dow Trades Above 25,000 as U.S.-China Trade Tensions Thaw

GE's $11.1 Billion Deal With Wabtec Should Have Warren Buffett Feeling Very Sad

GE's $11.1 Billion Deal With Wabtec Should Have Warren Buffett Feeling Very Sad

How to Trade Apple Ahead of Alphabet's Launch of YouTube Music

How to Trade Apple Ahead of Alphabet's Launch of YouTube Music

18 Top Stocks Hedge Funds Own That Goldman Sachs Thinks Will Keep Outperforming

18 Top Stocks Hedge Funds Own That Goldman Sachs Thinks Will Keep Outperforming

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Video: Why the Stock Market Is Discounting China Trade Fears for Now